There has been a business boom witnessed ever since 2021 came along. With companies eager to get going after the lull of a pandemic-infested 2020, there are a lot of investing options out there for people getting started in direct market access trading.
 
Coupa Software ($COUP) 

 
Coupa Software is a technology platform functioning globally, helping companies in business spend management. The company has been tasting growth as businesses depended on its high-tech solutions when the pandemic affected their supply chain. The renewed business activities in 2021 also helped the software company that has been growing its revenue for the past five years:  
 
  • For Q4 2021, Coupa is reporting record revenue worth $164 million, a massive year-over-year growth of 47% while quarterly calculated billings registered a year-over-year growth of 49% to hit $270 million.   
 
  • For Q3 2021 Coupa reported record revenue of $133 million, which is a year-over-year growth of 31%. Calculated billings were in the region of $140 million, registering a year-over-year growth of 33%.   
 
  • For Q2 2021, the software company reported revenue of $125.9 million, a 32% year-over-year growth. Subscription revenue was reported at $111.6 million, a 34% year-over-year growth.   
 
  • For Q1 2021 Coupa reported record revenue worth $119.2 million, a year-over-year growth of 47%. Subscription revenue also hit a record of $105.7 million, a year-over-year growth of 45%.       
     
Restaurant Brands International ($QSR) 
 
The owner of popular restaurant brands such as Burger King and Popeyes, among others, Restaurant Brands International (RBI) did suffer declining year-over-year revenue in Q3 and Q4 because of the Covid-19 pandemic, though 2021 Q1 saw the company beating expectations:  
 
  • For Q1 2021, the Burger King owner earned revenue worth $1.26 billion, beating expectations of $1.25 billion. Net income was reported at $270 million compared to $224 million from Q1 2020. 
 
  • For Q4 2020, RBI reported revenue worth $1,358 million compared to $1,475 million in Q4 2019.  
 
  • Q3 2020 saw RBI report revenue of $1,337 million compared to $1,458 million in Q3 2019.  
 
  • For Q2 2020, RBI reported revenue worth $1.05 billion, similar to expectations. Net income worth $163 million, though, was lower than $257 million reported in Q2 2019.  
 
Planet 13 ($PLNH.F) 
 
Las Vegas-based cannabis seller Planet 13 was affected by the Covid-19 pandemic though it did manage to report year-over-year revenue growth in Q3 and Q4 of 2020 as well as Q1 of 2021:  
 
  • For Q1 2021, the company reported revenue worth $23.8 million, 41.8% more than the $16.8 million earned in Q1 2020. It also earned net income worth $0.4 million compared to the $1.4 million net loss it incurred in Q1 2020.  
 
  • For Q4 2020, the cannabis company reported revenue worth $20.1 million, a year-over-year growth of 22%. However, this was still below the $23.1 million consensus estimate. Net loss was reported at $2.9 million.  
 
  • Q3 2020 saw Planet 13 report revenue worth $22.8 million, 36.5% greater than the $16.7 million earned in Q3 2019. It also earned net income worth $0.2 million, compared to net loss worth $1.7 million in Q3 2019.    
 
  • For Q2 2020, Planet 13 reported revenue worth $10.8 million, 34.9% lower than the $16.5 million earned in Q2 2019.  
 
Ocugen ($OCGN) 
 
Ocugen is a pharmaceutical company specializing in innovative gene therapy, and is making efforts to get Covaxin, the Covid-19 vaccine developed in India by the company’s partner Bharat Biotech, launched in the US. Though the FDA has denied emergency use authorization, efforts are on to get Covaxin approved more formally as a Covid-19 vaccine in the US. As a result, the company had to spend a great deal on research and development all through 2020 and into 2021:  
 
  • For Q1 2021, Ocugen reported cash and cash equivalents as well as restricted cash totaling $44.9 million, more than the $24.2 million it had reported as of the 31st of December 2020.  
 
  • Q4 2020 saw Ocugen report revenue worth $0.04 million, with cash and cash equivalents as well as restricted cash reported at $24.2 million, compared to $7.6 million in Q4 2019. 
 
  • For Q3 2020, Ocugen reported cash and cash equivalents as well as restricted cash worth $19.3 million. Research and development cost $1.5 million for the company compared to $1.3 million for Q3 2019. General and administrative expenses totaled $1.7 million, more than the $1.4 million spent in Q3 2019.  
 
  • For Q2 2020, Ocugen reported revenue worth $0.04 million. Net loss was reported at $3.6 million, more than the $3.5 million net loss reported in Q2 2019.  
 
With an experienced online stock brokerage, you can make use of the 2021 business boom and get started in trading stocks.  


DISCLAIMER
The content of this message and its attachments are intended only for the informational and educational use for the intended recipient and may contain confidential and privileged information. If you are not the intended recipient, any dissemination, distribution, or copying of this message or its attachments is prohibited. If you received this message in error, please notify the sender by replying to this email immediately and delete this message and its attachments from your computer. This content does not constitute an offer to sell or a solicitation to buy any security or instrument which may be referenced upon the site, or an offer to provide advisory or other services by the writer or company employing the writer in any jurisdiction in which such offer, solicitation, purchase or sale would be unlawful under the securities laws of such jurisdiction. All communications sent to or from TradeZero, Inc. are subject to archive and review by TradeZero, Inc. and by regulatory and law enforcement authorities. We explicitly disclaim all liability for any action taken based on any information contained in this writing.